IP Library Granted Patent US 8,722,422
Granted Patent B2
US 8,722,422 · App. 13/415,291 · Granted May 13, 2014

Uninterrupted flow pump apparatus and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,422
App. No.
13/415,291
Granted
May 13, 2014
Kind
B2
Abstract

This invention describes a method for pumping or delivering fluids utilizing a flexible vessel subject to controlled pressures within another pressure vessel. The pressure vessel can be sourced with positive and/or negative (e.g., vacuum) pressure.

Claims (29)

1. A method for providing substantially stable flow of a biological fluid comprising:

introducing said biological fluid into a sealed flexible chamber contained within an outer chamber that is adapted to provide a space containing a pressure sensitive medium around said sealed flexible chamber, the sealed flexible chamber comprising a fluid path between said sealed flexible chamber and the exterior of said outer chamber;

changing the pressure in a uniform and controlled manner within said space around said sealed flexible chamber, wherein said change in pressure is operable to send fluid from said sealed flexible chamber to a receiving container that is in fluid communication with said sealed flexible chamber with uninterrupted flow, and is operable to send fluid from said receiving container to said sealed flexible chamber with uninterrupted flow.

2. The method of claim 1 , wherein said biological fluid is pressure sensitive or flow sensitive.

3. The method of claim 1 , wherein said biological fluid comprises whole blood or blood components.

4. The method of claim 1 , wherein said biological fluid comprises a drug.

5. The method of claim 1 , wherein the contents of said sealed flexible chamber are sterile.

6. The method of claim 1 , wherein said sealed flexible chamber contains buffy coat.

7. The method of claim 1 , wherein said sealed flexible chamber comprises more than one fluid path between said sealed flexible chamber and said exterior of said outer chamber.

8. The method of claim 1 , wherein said fluid path between said sealed flexible chamber and said exterior of said outer chamber comprises at least one valve capable of controlling fluid flow through said fluid path.

9. The method of claim 1 further comprising monitoring one or more properties of fluid displaced into or out of said sealed flexible chamber using a load cell.

10. The method of claim 1 further comprising continuously increasing or decreasing pressure within said space around said sealed flexible chamber using a pressure reservoir.

11. A method for providing substantially stable flow of a biological fluid comprising:

introducing said biological fluid into a sealed flexible chamber contained within an outer chamber that provides a space containing a pressure sensitive medium around said sealed flexible chamber, said sealed flexible chamber comprising a fluid path between said sealed flexible chamber and an exterior of said outer chamber; and,

increasing or decreasing the pressure within said space around said sealed flexible chamber in a uniform and controlled manner using a pressure reservoir and a pressure valve, wherein said pressure reservoir is operable to send fluid from said sealed flexible chamber to a receiving container that is in fluid communication with said sealed flexible chamber with uninterrupted flow, and is operable to send fluid from said receiving container to said sealed flexible chamber with uninterrupted flow.

12. The method of claim 11 , wherein said fluid is pressure sensitive or flow sensitive.

13. The method of claim 11 , wherein said biological fluid comprises whole blood or blood components.

14. The method of claim 13 , wherein said blood components comprise white blood cells, red blood cells or plasma.

15. The method of claim 11 , wherein said biological fluid comprises a drug.

16. The method of claim 15 , wherein said drug is selected from the group consisting of insulin, interferon and erythropoietin.

17. The method of claim 11 , further comprising monitoring said increase or decrease of pressure within said space around said sealed flexible chamber.

18. The method of claim 11 , further comprising monitoring the properties of fluid displaced into or out of said sealed flexible chamber.

19. The method of claim 11 , wherein said pressure sensitive medium comprises air.

20. The method of claim 11 , wherein said pressure sensitive medium comprises a fluid.

21. The method of claim 11 , wherein the contents of said sealed flexible chamber are sterile.

22. The method of claim 11 , wherein said receiving container is in fluid communication with said sealed flexible chamber via a photoactivation element.

23. The method of claim 11 , wherein said sealed flexible chamber comprises more than one fluid path between said sealed flexible chamber and said exterior of said outer chamber.

24. The method of claim 11 , wherein said fluid path between said sealed flexible chamber and said exterior of said outer chamber comprises at least one valve capable of controlling fluid flow through said fluid path.

25. The method of claim 24 , further comprising controlling said at least one valve capable of controlling fluid flow through said fluid path.

Assignments (13)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0454 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 036662, FRAME 0053 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0503 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049822/0674 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 1, 2019
From: MALLINCKRODT CRITICAL CARE FINANCE INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 049643/0282 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 1, 2019
From: MALLINCKRODT PHARMA IP TRADING D.A.C.
To: MALLINCKRODT IP
Reel/Frame 049643/0348 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 1, 2019
From: MALLINCKRODT IP
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 049643/0397 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 1, 2019
From: THERAKOS, INC.
To: MALLINCKRODT CRITICAL CARE FINANCE INC.
Reel/Frame 049643/0168 →
SECURITY INTEREST Recorded Sep 25, 2015
From: THERAKOS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 036662/0053 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL AT REEL/FRAME NO. 29549/0074 Recorded Sep 25, 2015
From: ROYAL BANK OF CANADA
To: THERAKOS, INC.
Reel/Frame 036688/0833 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL AT REEL/FRAME NO. 29549/0119 Recorded Sep 25, 2015
From: ROYAL BANK OF CANADA
To: THERAKOS, INC.
Reel/Frame 036688/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2014
From: BRIGGS, DENNIS A.
To: THERAKOS, INC.
Reel/Frame 032231/0914 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 28, 2012
From: THERAKOS, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 029549/0074 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT (SECOND LIEN) Recorded Dec 28, 2012
From: THERAKOS, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 029549/0119 →